Comprehensive Analysis Based on the Cancer Immunotherapy and Immune Activation of Gastric Cancer Patients

Figure 8

(a) The OS between high- and low-expression of E2F2 groups; (b) the DSS between high- and low-expression of E2F2 groups; (c) the PFI between high- and low-expression of E2F2 groups; (d) the immune checkpoint-related genes between high- and low-expression of E2F2 groups; (e) the immune cell infiltration between high- and low-expression of E2F2 groups; (f) the TIDE score between high- and low-expression of E2F2 groups; (g) the ROC curve shows the predictive value of E2F2 in TCGA GC cohort.

(a)

(b)

(c)

(d)

(e)

(f)

(g)